Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses.
Journal
The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
03
09
2019
revised:
09
05
2020
accepted:
02
07
2020
entrez:
23
11
2020
pubmed:
24
11
2020
medline:
17
12
2020
Statut:
ppublish
Résumé
The burden of malaria infection in sub-Saharan Africa among school-aged children aged 5-15 years is underappreciated and represents an important source of human-to-mosquito transmission of Plasmodium falciparum. Additional interventions are needed to control and eliminate malaria. We aimed to assess whether preventive treatment of malaria might be an effective means of reducing P falciparum infection and anaemia in school-aged children and lowering parasite transmission. In this systematic review and two meta-analyses, we searched the online databases PubMed, Embase, Cochrane CENTRAL, and Clinicaltrials.gov for intervention studies published between Jan 1, 1990, and Dec 14, 2018. We included randomised studies that assessed the effect of antimalarial treatment among asymptomatic school-aged children aged 5-15 years in sub-Saharan Africa on prevalence of P falciparum infection and anaemia, clinical malaria, and cognitive function. We first extracted data for a study-level meta-analysis, then contacted research groups to request data for an individual participant data meta-analysis. Outcomes of interest included prevalence of P falciparum infection detected by microscopy, anaemia (study defined values or haemoglobin less than age-adjusted and sex-adjusted values), clinical malaria (infection and symptoms on the basis of study-specific definitions) during follow-up, and code transmission test scores. We assessed effects by treatment type and duration of time protected, and explored effect modification by transmission setting. For study-level meta-analysis, we calculated risk ratios for binary outcomes and standardised mean differences for continuous outcomes and pooled outcomes using fixed-effect and random-effects models. We used a hierarchical generalised linear model for meta-analysis of individual participant data. This study is registered with PROSPERO, CRD42016030197. Of 628 studies identified, 13 were eligible for the study-level meta-analysis (n=16 309). Researchers from 11 studies contributed data on at least one outcome (n=15 658) for an individual participant data meta-analysis. Interventions and study designs were highly heterogeneous; overall risk of bias was low. In the study-level meta-analysis, treatment was associated with reductions in P falciparum prevalence (risk ratio [RR] 0·27, 95% CI 0·17-0·44), anaemia (0·77, 0·65-0·91), and clinical malaria (0·40, 0·28-0·56); results for cognitive outcomes are not presented because data were only available for three trials. In our individual participant data meta-analysis, we found treatment significantly decreased P falciparum prevalence (adjusted RR [ARR] 0·46, 95% CI 0·40-0·53; p<0·0001; 15 648 individuals; 11 studies), anaemia (ARR 0·85, 0·77-0·92; p<0·0001; 15 026 individuals; 11 studies), and subsequent clinical malaria (ARR 0·50, 0·39-0·60; p<0·0001; 1815 individuals; four studies) across transmission settings. We detected a marginal effect on cognitive function in children older than 10 years (adjusted mean difference in standardised test scores 0·36, 0·01-0·71; p=0·044; 3962 individuals; five studies) although we found no significant effect when combined across all ages. Preventive treatment of malaria among school-aged children significantly decreases P falciparum prevalence, anaemia, and risk of subsequent clinical malaria across transmission settings. Policy makers and programme managers should consider preventive treatment of malaria to protect this age group and advance the goal of malaria elimination, while weighing these benefits against potential risks of chemoprevention. US National Institutes of Health and Burroughs Wellcome Fund/ASTMH Fellowship.
Sections du résumé
BACKGROUND
The burden of malaria infection in sub-Saharan Africa among school-aged children aged 5-15 years is underappreciated and represents an important source of human-to-mosquito transmission of Plasmodium falciparum. Additional interventions are needed to control and eliminate malaria. We aimed to assess whether preventive treatment of malaria might be an effective means of reducing P falciparum infection and anaemia in school-aged children and lowering parasite transmission.
METHODS
In this systematic review and two meta-analyses, we searched the online databases PubMed, Embase, Cochrane CENTRAL, and Clinicaltrials.gov for intervention studies published between Jan 1, 1990, and Dec 14, 2018. We included randomised studies that assessed the effect of antimalarial treatment among asymptomatic school-aged children aged 5-15 years in sub-Saharan Africa on prevalence of P falciparum infection and anaemia, clinical malaria, and cognitive function. We first extracted data for a study-level meta-analysis, then contacted research groups to request data for an individual participant data meta-analysis. Outcomes of interest included prevalence of P falciparum infection detected by microscopy, anaemia (study defined values or haemoglobin less than age-adjusted and sex-adjusted values), clinical malaria (infection and symptoms on the basis of study-specific definitions) during follow-up, and code transmission test scores. We assessed effects by treatment type and duration of time protected, and explored effect modification by transmission setting. For study-level meta-analysis, we calculated risk ratios for binary outcomes and standardised mean differences for continuous outcomes and pooled outcomes using fixed-effect and random-effects models. We used a hierarchical generalised linear model for meta-analysis of individual participant data. This study is registered with PROSPERO, CRD42016030197.
FINDINGS
Of 628 studies identified, 13 were eligible for the study-level meta-analysis (n=16 309). Researchers from 11 studies contributed data on at least one outcome (n=15 658) for an individual participant data meta-analysis. Interventions and study designs were highly heterogeneous; overall risk of bias was low. In the study-level meta-analysis, treatment was associated with reductions in P falciparum prevalence (risk ratio [RR] 0·27, 95% CI 0·17-0·44), anaemia (0·77, 0·65-0·91), and clinical malaria (0·40, 0·28-0·56); results for cognitive outcomes are not presented because data were only available for three trials. In our individual participant data meta-analysis, we found treatment significantly decreased P falciparum prevalence (adjusted RR [ARR] 0·46, 95% CI 0·40-0·53; p<0·0001; 15 648 individuals; 11 studies), anaemia (ARR 0·85, 0·77-0·92; p<0·0001; 15 026 individuals; 11 studies), and subsequent clinical malaria (ARR 0·50, 0·39-0·60; p<0·0001; 1815 individuals; four studies) across transmission settings. We detected a marginal effect on cognitive function in children older than 10 years (adjusted mean difference in standardised test scores 0·36, 0·01-0·71; p=0·044; 3962 individuals; five studies) although we found no significant effect when combined across all ages.
INTERPRETATION
Preventive treatment of malaria among school-aged children significantly decreases P falciparum prevalence, anaemia, and risk of subsequent clinical malaria across transmission settings. Policy makers and programme managers should consider preventive treatment of malaria to protect this age group and advance the goal of malaria elimination, while weighing these benefits against potential risks of chemoprevention.
FUNDING
US National Institutes of Health and Burroughs Wellcome Fund/ASTMH Fellowship.
Identifiants
pubmed: 33222799
pii: S2214-109X(20)30325-9
doi: 10.1016/S2214-109X(20)30325-9
pmc: PMC7721819
mid: NIHMS1648016
pii:
doi:
Substances chimiques
Antimalarials
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1499-e1511Subventions
Organisme : NIAID NIH HHS
ID : K23 AI135076
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI114996
Pays : United States
Organisme : FIC NIH HHS
ID : K43 TW010365
Pays : United States
Organisme : Medical Research Council
ID : MR/K00736X/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Glob Health. 2018 Jun;6(6):e668-e679
pubmed: 29661635
PLoS Med. 2016 Nov 22;13(11):e1002175
pubmed: 27875528
Malar J. 2010 Jan 04;9:2
pubmed: 20044942
Malar J. 2015 Nov 14;14:450
pubmed: 26574017
Am J Trop Med Hyg. 2013 Jun;88(6):1102-1108
pubmed: 23589533
Trop Med Int Health. 2009 Jul;14(7):784-91
pubmed: 19497079
J Infect Dis. 2016 Jan 1;213(1):90-9
pubmed: 26142435
Public Health Nutr. 2002 Jun;5(3):413-8
pubmed: 12003652
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD009085
pubmed: 22161444
Trop Med Int Health. 2002 Feb;7(2):104-17
pubmed: 11841700
Nutrients. 2016 Nov 02;8(11):
pubmed: 27827838
J Nutr. 2010 Mar;140(3):635-41
pubmed: 20107144
PLoS Med. 2016 Jan 19;13(1):e1001942
pubmed: 26783752
Malar J. 2017 Nov 09;16(1):456
pubmed: 29121931
PLoS One. 2010 Oct 19;5(10):e13438
pubmed: 20976051
Clin Infect Dis. 2014 May;58(10):1404-12
pubmed: 24621953
Malar J. 2016 Apr 18;15:219
pubmed: 27091046
Malar J. 2011 Dec 20;10:378
pubmed: 22185615
J Infect Dis. 1995 Jun;171(6):1569-75
pubmed: 7769294
Bull World Health Organ. 2003;81(3):205-16
pubmed: 12764517
Parasitol Today. 2000 May;16(5):183-6
pubmed: 10782073
Malar J. 2019 Sep 18;18(1):318
pubmed: 31533845
Lancet. 2008 Nov 1;372(9649):1545-54
pubmed: 18984187
Malar J. 2018 Apr 3;17(1):147
pubmed: 29615044
Lancet. 2008 Jul 12;372(9633):127-38
pubmed: 18620950
Lancet. 2008 Nov 1;372(9649):1555-62
pubmed: 18984188
PLoS One. 2012;7(10):e46042
pubmed: 23056232
Nat Commun. 2012;3:1237
pubmed: 23212366
Cochrane Database Syst Rev. 2004;(2):CD000363
pubmed: 15106149
BMJ Glob Health. 2017 Jun 28;2(2):e000182
pubmed: 29081992
Parasite Epidemiol Control. 2018 Feb 07;3(2):96-105
pubmed: 29988270
Glob Health Action. 2016 Sep 14;9:32197
pubmed: 27633035
PLoS Med. 2014 Jan 28;11(1):e1001594
pubmed: 24492859
Malar J. 2018 Apr 16;17(1):166
pubmed: 29661245
Lancet. 2009 Oct 31;374(9700):1533-42
pubmed: 19765816
Int J Antimicrob Agents. 2017 Mar;49(3):339-347
pubmed: 28108368
PLoS One. 2015 Mar 13;10(3):e0118901
pubmed: 25768015
Am J Hum Biol. 2005 May-Jun;17(3):280-92
pubmed: 15849701
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003756
pubmed: 22336792
CMAJ. 2013 Nov 19;185(17):E791-802
pubmed: 24130243
PLoS One. 2016 Jun 09;11(6):e0156717
pubmed: 27281028
Lancet. 2018 Feb 17;391(10121):687-699
pubmed: 29153316
Malar J. 2016 Nov 14;15(1):553
pubmed: 27842542
Nat Commun. 2017 Oct 26;8(1):1133
pubmed: 29074880
PLoS One. 2015 Jul 24;10(7):e0134061
pubmed: 26207758
Adv Parasitol. 2002;52:235-64
pubmed: 12521262
Lancet Infect Dis. 2018 Apr;18(4):e119-e132
pubmed: 29395997
Am J Trop Med Hyg. 2006 Mar;74(3):386-93
pubmed: 16525095
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5649-54
pubmed: 27401569
Trop Med Int Health. 2014 Nov;19(11):1294-309
pubmed: 25145389